Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

Patrick Gage, Ph.D., executive chairman of PDL's board of directors. "Although we're surprised and disappointed by the Nuvion results in IVSR-UC, we're fortunate to have a portfolio of multiple candidates consistent with our longer-term focus in the targeted areas of oncology and immunology, as well as sufficient resources to advance these opportunities."

Nuvion (visilizumab) Pivotal Program Termination

Following review of data communicated by the Nuvion DMC this past Friday, August 24, PDL has decided that it will no longer pursue its phase 3 program of visilizumab in IVSR-UC, including both the RESTORE 1 and RESTORE 2 studies. The DMC interim evaluation included data from 91 patients in the RESTORE 1 trial at the 45-day primary endpoint. The analysis showed insufficient efficacy and an inferior safety profile in the visilizumab arm compared to IV steroids alone. The company is currently reviewing whether to continue the ongoing dose-ranging trial while it thoroughly evaluates the broader implications of these very recent results to the overall visilizumab program.

New Strategic Direction and Organizational Alignment

PDL has revised its corporate strategy to take advantage of its deep clinical and pre-clinical portfolio, and leverage its ability to innovate in the science and development of monoclonal antibodies. PDL will focus its research and development initiatives and strengthen its expertise in two therapeutic areas -- oncology and select immunological diseases. In oncology, the company's programs include volociximab in a number of solid tumors, HuLuc63 in multiple myeloma, PDL 192 in preclinical development and several additional research stage candidates. PDL's immunological programs include daclizumab in multiple sclerosis and other indications, visilizumab in various potential indications and several preclinical candidates. The company is planning a research and development update in mid-November to detail the status of its R&D init
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 PathoGenetix, Inc., a commercial-stage ... typing, announced today that it has successfully identified and ... strains obtained from the Centers for Disease Control and ... technology. The findings are detailed in a poster ... Society for Microbiology in Denver on Monday. , The ...
(Date:5/20/2013)... Al Khaimah, UAE (PRWEB) May 21, 2013 ... private equity consultancy specializing in “game-changing” life science and ... of Ms. Dalia Dergham to its International Project Team. ... to bring even greater multi-cultural depth to Grace Century ... projects around the globe. , Ms. Dergham holds both ...
(Date:5/20/2013)... CHATSWORTH, Calif. , May 20, 2013 /PRNewswire/ ... company providing naturally based products across a broad ... the company has retained investor relations firm, BlueWater ... during the return to trading process, and to ... post trading initiation. Matthew ...
(Date:5/20/2013)... ROCKVILLE , Md. and BALTIMORE ... Inc. (BHI), a regional private-public partnership focusing ... to early-stage funding in Central Maryland ... Aiyar, Ph.D., M.B.A., as the first Entrepreneur-in-Residence (EIR) ... (NIH) National Heart, Lung and Blood Institute ...
Breaking Biology Technology:New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Dalia Dergham Joins Grace Century FZ LLC International Project Team 2Pacific Shore Holdings Retains Investor Relations Firm 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4
... Feb. 23 WaferGen Biosystems,Inc. (OTC Bulletin ... gene,expression, genotyping, cell biology and stem cell ... of the company,s SmartChip Real-Time PCR,System will ... Molecular Medicine Tri-Conference. The data will ...
... patients with acute coronary syndrome (ACS) undergoing an artery-opening ... help prevent heart attacks. Daiichi Sankyo Company, Limited ... LLY ) announced today that the European Commission ... Ef-ee-ent) (prasugrel) for the prevention of atherothrombotic ...
... Feb. 23 In 2008, Abbott,s,( NYSE: ABT ) ... records both,in terms of number of participating employees and ... out of every four Abbott,employees (74 percent) participated in ... 2007. Abbott employees contributed more than $12.6,million to ...
Cached Biology Technology:Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 3European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI 2European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI 3European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI 4European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI 5Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 2Abbott Employee Giving Sets New Records for Employee Participation and Total Donations 3
(Date:5/21/2013)... pharmacies and health stores, phosphatidylserine is a natural ... Proven to improve cognition and slow memory loss, ... memory impairment. Now a team headed by Prof. ... Aviv University,s Department of Human Molecular Genetics ... the functioning of genes involved in degenerative brain ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
(Date:5/20/2013)... 2013) University of Minnesota Medical School researchers from ... with the University,s Brain Tumor Program, have developed a ... (MPNST) that allow them to discover new genes and ... research was published this week in the journal ... method, researchers in the lab of David Largaespada, Ph.D., ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2
... innovative North-South research collaboration has culminated in a study published ... develop new ways to treat or prevent East Coast fever. ... in East and Central Africa, has had a devastating impact ... ?where cattle play a crucial role in the local society ...
... Duke neuroscientists Catalin Buhusi and Warren Meck. And understanding ... all its functions. The brain's internal clocks coordinate a ... to getting food, they said. , In a review ... and Meck discuss the current state of understanding of ...
... a fungus that deprives about 60 million people a year ... molecular machinery that enables the pathogen to blast its way ... known as rice blast fungus, is the most deadly of ... as 75 percent in infected areas. Learning how the fungus ...
Cached Biology News:US/African project deciphers deadly parasite genome 2US/African project deciphers deadly parasite genome 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 2What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 4Purdue researchers find key to rice blast fungus 2Purdue researchers find key to rice blast fungus 3
... Covance has generated hybridomas against ... to project initiation, you are provided ... consultation. Hybridoma cell lines developed by ... client. A typical hybridoma development project ...
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... Packaging Extracts are optimized for maximum packaging ... The high efficiency extracts (> 109 pfu/g ... produce a library containing at least 5 ... The extracts are made from a specially ...
... The Panorama Mouse/Rat Tissue Extract Protein Array ... in various tissue extracts. The expression of ... using a protein specific antibody. When the ... visualized by a sensitive chemiluminescent or fluorescent ...
Biology Products: